Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;207(5):2173-2177.
doi: 10.1111/bjh.70137. Epub 2025 Sep 11.

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy

Andrea Kuhnl  1 , S Bouziana  1 , S F Barrington  2 , S Galani  3 , T Menne  4 , M Northend  3 , L Stevens  3 , S Kamat  5 , W Osborne  4   6 , R Johnson  7 , E Kumar  1 , R Sanderson  1 , P E M Patten  1   8 , R Benjamin  1   9 , J Frew  4 , R Prestwich  7 , J L Brady  10 , N G Mikhaeel  10
Affiliations

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy

Andrea Kuhnl et al. Br J Haematol. 2025 Nov.
No abstract available

Keywords: CAR T‐cell therapy; bridging therapy; non‐Hodgkin lymphoma; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

A.K. has served on advisory boards and received honoraria from Kite/Gilead, Novartis, Abbvie, Roche and BMS. M.N. received honoraria from Kite/Gilead. R.S. has served on advisory boards and received honoraria from Kite/Gilead and Novartis. R.J. has served on advisory boards and received honoraria from Kite/Gilead. W.O. has received honoraria from Roche, Takeda, Pfizer, Servier, Kite/Gilead, MSD, Novartis, Beigene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, BMS, Janssen. The remaining authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Progression‐free survival of the combined cohort.
See this image and copyright information in PMC

References

    1. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR‐HEMATOTOX: a model for CAR T‐cell related hematological toxicity in relapsed/refractory large B‐cell lymphoma. Blood. 2020;136:41–42. - PMC - PubMed
    1. Deselm C. The current and future role of radiation therapy in the era of CAR T‐cell salvage. Br J Radiol. 2021;94:20210098. - PMC - PubMed
    1. Figura NB, Jain MD, Sim AJ. Patterns of failure following chimeric antigen receptor Tcell (CAR‐T) therapy. Int J Radiat Oncol. 2019;105:136.
    1. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B‐cell lymphoma. Blood Adv. 2020;4:2871–2883. 10.1182/bloodadvances.2020001837 - DOI - PMC - PubMed
    1. Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA/DRST real‐world outcome analysis of CAR‐T cell therapies for large B‐cell lymphoma in Germany. Blood. 2022;140:349–358. 10.1182/blood.2021015209 - DOI - PubMed

Grants and funding

LinkOut - more resources